News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nordic Nanovector: Betalutin™ Granted Orphan-Drug Designation In The USA


5/20/2014 8:32:50 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OSLO, Norway--(BUSINESS WIRE)--Nordic Nanovector is pleased to announce today that the company’s lead product candidate Betalutin™ has been granted orphan-drug designation for treatment of follicular lymphoma in the USA by FDA’s Office of Orphan Products Development.

Orphan-drug designation for Betalutin™ will provide the company several advantages, including reduced costs related to the clinical development program, as well as commercial exclusivity for seven years once the product reaches the market.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Lymphoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES